Molecular Prognostic Profile of Egyptian HCC Cases Infected with Hepatitis C Virus

Zekri, Abdel‐Rahman N.; Hassan, Zeinab K.; Bahnassy, Abeer A.; Sherif, Ghada M.; El-Dahshan, Dina H.; Abouelhoda, Mohamed; Ali, Ahmed Yousif; Hafez, Mohamed M.

doi:10.7314/apjcp.2012.13.11.5433

Cited by 25 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was in agreement with the results of El-Serag[2], Zidan et al[23] and Zekri et al[24] and reflects the close relationship between HCV and HCC. The prevalence of HCV infection in Egypt is high and its percentage in patients who develop HCC is higher than that in patients in other countries[25,26].…”

Section: Discussionsupporting

confidence: 93%

Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients

Shaker¹,

Fattah²,

Sabbour³

et al. 2017

WJH

View full text Add to dashboard Cite

AIMTo investigate the clinical utility of serum annexin A2 (ANXA2) as a diagnostic marker for early hepatocellular carcinoma (HCC).METHODSThis study was performed in HCC Clinic of Ain Shams University Hospitals, Cairo, Egypt and included: Group 1: Fifty patients with early stage HCC (Barcelona Clinic Liver Cancer stage A); Group 2: Twenty five patients with chronic liver disease; and Control Group: Fifteen healthy, age- and sex-matched subjects who were seronegative for viral hepatitis markers. The following laboratory investigations were done: Viral hepatitis markers [hepatitis B surface antigen and hepatitis C virus (HCV) antibodies], HCV RNA in HCV antibody-positive patients, serum alpha fetoprotein (AFP), and serum ANXA2 levels.RESULTSIn this study, 88% of HCC patients (n = 44) were HCV-positive, while HBV infection represented only 8% of all HCC patients (n = 4); and two patients were negative for both viral markers. A highly significant difference was found between patients with HCC and chronic liver disease as well as controls with regard to serum ANXA2 levels (130, IQR 15-240; 15, IQR 15-17; and 17, IQR 15-30 ng/mL, respectively). The area under the curve of ANXA2 was 0.865; the cut-off value was established to be 18 ng/mL with a diagnostic sensitivity of 74% and a specificity of 88%, while the sensitivity and specificity of AFP at the cut-off value of 200 ng/dL were 20% and 100%, respectively.CONCLUSIONSerum ANXA2 may serve as a biomarker for the early detection of HCC.

show abstract

Section: Discussionsupporting

confidence: 93%

Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients

Shaker¹,

Fattah²,

Sabbour³

et al. 2017

WJH

View full text Add to dashboard Cite

show abstract

“…Increased expression of CYP7A1 has been previously determined using quantitative RT‐PCR in patients with HCC (50). Similarly, the increased expression of ELOVL2 has been detected by RT‐PCR in the liver tissue of 31 patients with HCC (51). The ELOVL2 gene has a role in oxidative stress induction and lipid biosynthesis through elongation of long‐chain fatty acids.…”

Section: Resultsmentioning

confidence: 87%

The human liver‐specific proteome defined by transcriptomics and antibody‐based profiling

Kampf

Mardinoğlu²,

Fagerberg

et al. 2014

FASEB j.

View full text Add to dashboard Cite

Human liver physiology and the genetic etiology of the liver diseases can potentially be elucidated through the identification of proteins with enriched expression in the liver. Here, we combined data from RNA sequencing (RNA-Seq) and antibody-based immunohistochemistry across all major human tissues to explore the human liver proteome with enriched expression, as well as the cell type-enriched expression in hepatocyte and bile duct cells. We identified in total 477 protein-coding genes with elevated expression in the liver: 179 genes have higher expression as compared to all the other analyzed tissues; 164 genes have elevated transcript levels in the liver shared with at least one other tissue type; and an additional 134 genes have a mild level of increased expression in the liver. We identified the precise localization of these proteins through antibody-based protein profiling and the subcellular localization of these proteins through immunofluorescent-based profiling. We also identified the biological processes and metabolic functions associated with these proteins, investigated their contribution in the occurrence of liver diseases, and identified potential targets for their treatment. Our study demonstrates the use of RNA-Seq and antibody-based immunohistochemistry for characterizing the human liver proteome, as well as the use of tissue-specific proteins in identification of novel drug targets and discovery of biomarkers.-Kampf, C., Mardinoglu, A., Fagerberg, L., Hallström, B. M., Edlund, K., Lundberg, E., Pontén, F., Nielsen, J., Uhlen, M. The human liver-specific proteome defined by transcriptomics and antibody-based profiling.

show abstract

“…In Egypt, which has a very high incidence of hepatitis C virus (HCV) infection, most malignant neoplasms of the liver arise on top of chronically damaged livers, typically a cirrhotic liver [1]. …”

Section: Introductionmentioning

confidence: 99%

Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease

et al. 2014

View full text Add to dashboard Cite

IntroductionWe have assessed the utility of autologous mesenchymal stem cell (MSC) peripheral vein infusion as a possible therapeutic modality for patients with end-stage liver diseases.MethodsForty patients with post-hepatitis C virus (HCV) end-stage liver disease were randomized into two groups: Group 1 (GI): 20 patients who received granulocyte colony-stimulating factor (G-CSF) for 5 days followed by autologous MSCs peripheral-vein infusion and group 2 (GII): 20 patients who received regular liver-supportive treatment only (control group).ResultsIn MSC-infused patients (GI), 54% showed near normalization of liver enzymes and improvement in liver synthetic function. Significant changes were reported in albumin (P = 0.000), bilirubin (P = 0.002), increased international normalized ratio (INR) (P = 0.017), prothrombin concentration (P = 0.029) and alanine transaminase (ALT) levels (P = 0.029), with stabilization of clinical and biochemical status in 13% of cases. None of the patients in GII showed any significant improvement. Hepatic fibrosis was assessed in GI by detection of procollagen IIIC peptide level (PIIICP) and procollagen III N peptide level (PIIINP). The pretreatment values of s-PIIICP and s-PIIINP were 9.4 ± 4.2 and 440 ± 189, respectively, with a decrease to 8.1 ± 2.6 and 388 ± 102, respectively, 3 months after MSC therapy. However, the difference was statistically nonsignificant (P = 0.7). A significant correlation coefficient was reported after 3 months between the s-PIIINP and prothrombin concentration (P = -0.5) and between s-PIIICP and ascites (P = 0.550).ConclusionsFirst, autologous MSC infusion into a peripheral vein is as effective as the previously reported intrahepatic infusion. Second, MSCs have a supportive role in the treatment of end-stage liver disease, with satisfactory tolerability and beneficial effects on liver synthetic functions and hepatic fibrosis. Third, IV infusion of MSCs after G-CSF mobilization improves s-albumin within the first 2 weeks and prothrombin concentration and alanine Taransaminase after 1 month. According to the data from this current study and those previously reported by our group, we recommend further studies on patients’ infusion with pure CD133 and CD34 followed by IV infusion of in vitro-differentiated MSCs within 1 week and another infusion after 3 months.Trial registrationClinicalTrials.gov NCT01729221. Registered 17 November 2012.

show abstract

Molecular Prognostic Profile of Egyptian HCC Cases Infected with Hepatitis C Virus

Cited by 25 publications

References 26 publications

Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients

Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients

The human liver‐specific proteome defined by transcriptomics and antibody‐based profiling

Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease

Contact Info

Product

Resources

About